Unknown

Dataset Information

0

Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy.


ABSTRACT: We present a mechanistic mathematical model of immune checkpoint inhibitor therapy to address the oncological need for early, broadly applicable readouts (biomarkers) of patient response to immunotherapy. The model is built upon the complex biological and physical interactions between the immune system and cancer, and is informed using only standard-of-care CT. We have retrospectively applied the model to 245 patients from multiple clinical trials treated with anti-CTLA-4 or anti-PD-1/PD-L1 antibodies. We found that model parameters distinctly identified patients with common (n = 18) and rare (n = 10) malignancy types who benefited and did not benefit from these monotherapies with accuracy as high as 88% at first restaging (median 53 days). Further, the parameters successfully differentiated pseudo-progression from true progression, providing previously unidentified insights into the unique biophysical characteristics of pseudo-progression. Our mathematical model offers a clinically relevant tool for personalized oncology and for engineering immunotherapy regimens.

SUBMITTER: Butner JD 

PROVIDER: S-EPMC7190324 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy.

Butner Joseph D JD   Elganainy Dalia D   Wang Charles X CX   Wang Zhihui Z   Chen Shu-Hsia SH   Esnaola Nestor F NF   Pasqualini Renata R   Arap Wadih W   Hong David S DS   Welsh James J   Koay Eugene J EJ   Cristini Vittorio V  

Science advances 20200429 18


We present a mechanistic mathematical model of immune checkpoint inhibitor therapy to address the oncological need for early, broadly applicable readouts (biomarkers) of patient response to immunotherapy. The model is built upon the complex biological and physical interactions between the immune system and cancer, and is informed using only standard-of-care CT. We have retrospectively applied the model to 245 patients from multiple clinical trials treated with anti-CTLA-4 or anti-PD-1/PD-L1 anti  ...[more]

Similar Datasets

| S-EPMC8036568 | biostudies-literature
| S-EPMC6684862 | biostudies-literature
| S-EPMC8264884 | biostudies-literature
| S-EPMC10712712 | biostudies-literature
| S-EPMC9735726 | biostudies-literature
| S-EPMC8195413 | biostudies-literature
| S-EPMC10989074 | biostudies-literature
| S-EPMC8237437 | biostudies-literature